Earnings Call · Q2 FY2022·2022-08-07

Q2 22EPS -40.00%·Rev n/aQ1 22EPS -100.00%*·Rev n/aQ4 21EPS -30.30%·Rev n/aQ3 21EPS +11.54%·Rev n/a⚠ consensus missing

Theravance Biopharma, Inc. TBPH

Gail Cohen — Investor Relations or Communications Officer

Rick Winningham — Chief Executive Officer

Rhonda Farnum — Commercial Leader or Sales/Marketing Executive

Rick Graham — Chief Medical Officer or Head of Clinical Development

Andrew Hindman — Chief Financial Officer

−7.8%1d on move date−7.6% vs SPY3d−5.1%5d−0.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TBPH calls or request research access.

More TBPH calls Browse calls Request research access